Evidence map›Paper›PMID 37339441›Full record

Trial reportJournal of child and adolescent psychopharmacology2023

d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and

Andrew J Cutler, Katsumi Suzuki, Brittney Starling, Kanan Balakrishnan, Marina Komaroff, Suzanne Meeves, Mariacristina Castelli, Ann Childress

Erratum issuedOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

  • Erratum issued
    2023
5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Andrew J CutlerDepartment of Psychiatry, SUNY Upstate Medical University, Neuroscience Education Institute, Lakewood Ranch, Florida, USA.ORCID 0000-0001-5800-0378
Katsumi SuzukiProduct Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersey, USA.
Brittney StarlingProduct Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersey, USA.
Kanan BalakrishnanProduct Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersey, USA.
Marina KomaroffProduct Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersey, USA.
Suzanne MeevesProduct Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersey, USA.
Mariacristina CastelliProduct Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersey, USA.
Ann ChildressCenter for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, USA.ORCID 0000-0001-5782-7891
Jersey City Medical Center · USCenter for Psychiatry and Behavioral Medicine · USSUNY Upstate Medical University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsAdolescentChildDextroamphetamineDose-Response Relationship, DrugHumansTreatment OutcomeCentral Nervous System StimulantsDextroamphetamineADHDamphetamineeffect sizenumber needed to treattransdermal

Identifiers

PMID37339441
PMCPMC10282809
OpenAlexW4381331292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.